Perimenopausal period and mood disorders

The article is devoted to the possibilities of correction of neuropsychiatric disorders in perimenopause, a condition associated with the cessation of menstruation in a woman and a decrease in the level of ovarian steroid hormones (estrogen and progesterone) due to the loss of the ovarian follicular mass. It is known that biological and endocrine changes during this period are often accompanied by autonomic symptoms. In perimenopause, women may experience symptoms such as hot flashes and night sweats, insomnia, vaginal dryness, mood disorders, etc. Although most symptoms are not life-threatening, they can have a negative impact on the quality of life, physical and mental health of perimenopausal women. During menopause, women are at higher risk of developing depression, stress, anxiety and emotional disorders. In addition, during perimenopause, women experience not only depressive symptoms but also cognitive impairment, which may be related to changes in hormonal background. Drugs that are used in the treatment of mood disorders affect different neurotransmitters, in particular serotonin, norepinephrine and gamma-aminobutyric acid (GABA). One of the benzodiazepine derivatives is Tofisopam, first developed in Hungary and marketed in a number of European countries under the name Grandaxin. It is indicated for the treatment of neurotic and somatic disorders associated with tension, anxiety, autonomic disorders, lack of energy and motivation, apathy, fatigue, depressed mood and alcohol withdrawal syndrome, including during perimenopause. Tofisopam has good anxiolytic activity with no observable sedative, anticonvulsant, amnestic or muscle relaxant effects.

1. Xiao C., Mou C., Zhou X. Effect of Mindfulness Meditation Training on Anxiety, Depression and Sleep Quality in Perimenopausal Women. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(8):998–1002. doi: 10.12122/j.issn.1673-4254.2019.08.19.

2. Lobo R.A. Menopause and Sexuality: Is There a Role for Androgen Therapy? Menopause Management for the Millennium. Available at: https://www.medscape.org/viewarticle/413064_25.

3. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168. doi: 10.1210/jc.2011-3362.

4. Soules M.R., Sherman S., Parrott E., Rebar R., Santoro N., Utian W., Woods N. Executive Summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;76(5):874–878. doi: 10.1016/s0015-0282(01)02909-0.

5. Liu M., Wang Y., Li X., Liu P., Yao C., Ding Y. et al. A Health Survey of Beijing Middle-Aged Registered Nurses during Menopause. Maturitas. 2013;74(1):84–88. doi: 10.1016/j.maturitas.2012.10.006.

6. Jaspers L., Daan N.M., van Dijk G.M., Gazibara T., Muka T., Wen K.X. et al. Health in Middle-Aged and Elderly Women: A Conceptual Framework for Healthy Menopause. Maturitas. 2015;81(1):93–98. doi: 10.1016/j.maturitas.2015.02.010.

7. Hulka B.S., Meirik O. Research on the Menopause. Maturitas. 1996;23(2): 109–112. doi: 10.1016/0378-5122(95)00967-1.

8. Yim G., Ahn Y., Chang Y., Ryu S., Lim J.Y., Kang D. et al. Prevalence and Severity of Menopause Symptoms and Associated Factors Across Menopause Status in Korean Women. Menopause. 2015;22(10):1108–1116. doi: 10.1097/GME.0000000000000438.

9. Moilanen J., Aalto A.M., Hemminki E., Aro A.R., Raitanen J., Luoto R. Prevalence of Menopause Symptoms and Their Association with Lifestyle among Finnish Middle-Aged Women. Maturitas. 2010;67(4):368–374. doi: 10.1016/j.maturitas.2010.08.007.

10. El Shafie K., Al Farsi Y., Al Zadjali N., Al Adawi S., Al Busaidi Z., Al Shafaee M. Menopausal Symptoms among Healthy, Middle-Aged Omani Women as Assessed with the Menopause Rating Scale. Menopause. 2011;18(10):1113–1119. doi: 10.1097/gme.0b013e31821b82ee.

11. Pérez J.A., Garcia F.C., Palacios S., Pérez M. Epidemiology of Risk Factors and Symptoms Associated with Menopause in Spanish Women. Maturitas. 2009;62(1):30–36. doi: 10.1016/j.maturitas.2008.10.003.

12. Greenblum C.A., Rowe M.A., Neff D.F., Greenblum J.S. Midlife Women: Symptoms Associated with Menopausal Transition and Early Postmenopause and Quality of Life. Menopause. 2013;20(1):22–27. doi: 10.1097/gme.0b013e31825a2a91.

13. Kim Y., Austin S.B., Subramanian S.V., Kawachi I. Body Weight Perception, Disordered Weight Control Behaviors, and Depressive Symptoms among Korean Adults: The Korea National Health and Nutrition Examination Survey 2014. PLoS One. 2018;13(6):e0198841. doi: 10.1371/journal.pone.0198841.

14. Al-Safi Z.A., Santoro N. Menopausal Hormone Therapy and Menopausal Symptoms. Fertil Steril. 2014;101(4):905–915. doi: 10.1016/j.fertnstert.2014.02.032.

15. Monteleone P., Mascagni G., Giannini A., Genazzani A.R., Simoncini T. Symptoms of Menopause – Global Prevalence, Physiology and Implications. Nat Rev Endocrinol. 2018;14(4):199–215. doi: 10.1038/nrendo.2017.180.

16. Guthrie J.R., Dennerstein L., Taffe J.R., Donnelly V. Health Care-Seeking for Menopausal Problems. Climacteric. 2003;6(2):112–117. doi: 10.1080/cmt.6.2.112.117.

17. Llaneza P., García-Portilla M.P., Llaneza-Suárez D., Armott B., Pérez-López F.R. Depressive Disorders and the Menopause Transition. Maturitas. 2012;71(2):120–130. doi: 10.1016/j.maturitas.2011.11.017.

18. Cohen L.S., Soares C.N., Vitonis A.F., Otto M.W., Harlow B.L. Risk for New Onset of Depression during the Menopausal Transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2006;63(4):385–390. doi: 10.1001/archpsyc.63.4.385.

19. Melby M.K., Lock M., Kaufert P. Culture and Symptom Reporting at Menopause. Hum Reprod Update. 2005;11(5):495–512. doi: 10.1093/humupd/dmi018.

20. ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202–216. doi: 10.1097/01.AOG.0000441353.20693.78.

21. Politi M.C., Schleinitz M.D., Col N.F. Revisiting the Duration of Vasomotor Symptoms of Menopause: A Meta-Analysis. J Gen Intern Med. 2008;23(9):1507–1513. doi: 10.1007/s11606-008-0655-4.

22. Zheng H., Harlow S.D., Kravitz H.M., Bromberger J., Buysse D.J., Matthews K.A. et al. Actigraphy-Defined Measures of Sleep and Movement across the Menstrual Cycle in Midlife Menstruating Women: Study of Women’s Health Across the Nation Sleep Study. Menopause. 2015;22(1):66–74. doi: 10.1097/GME.0000000000000249.

23. Kravitz H.M., Zhao X., Bromberger J.T., Gold E.B., Hall M.H., Matthews K.A., Sowers M.R. Sleep Disturbance during the Menopausal Transition in a Multi-Ethnic Community Sample of Women. Sleep. 2008;31(7): 979–990. doi: 10.5665/sleep/31.7.979.

24. Guérin E., Goldfield G., Prud’homme D. Trajectories of Mood and Stress and Relationships with Protective Factors during the Transition to Menopause: Results using Latent Class Growth Modeling in a Canadian Cohort. Arch Womens Ment Health. 2017;20(6):733–745. doi: 10.1007/s00737-017-0755-4.

25. Gold E.B., Sternfeld B., Kelsey J.L., Brown C., Mouton C., Reame N. et al. Relation of Demographic and Lifestyle Factors to Symptoms in a MultiRacial/Ethnic Population of Women 40–55 Years of Age. Am J Epidemiol. 2000;152(5):463–473. doi: 10.1093/aje/152.5.463.

26. Schmidt P.J., Ben Dor R., Martinez P.E., Guerrieri G.M., Harsh V.L., Thompson K. et al. Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(7):714–726. doi: 10.1001/jamapsychiatry.2015.0111.

27. Rubinow D.R., Johnson S.L., Schmidt P.J., Girdler S., Gaynes B. Efficacy of Estradiol in Perimenopausal Depression: So Much Promise and So Few Answers. Depress Anxiety. 2015;32(8):539–549. doi: 10.1002/da.22391.

28. Soares C.N. Depression and Menopause: An Update on Current Knowledge and Clinical Management for this Critical Window. Med Clin North Am. 2019;103(4):651–667. doi: 10.1016/j.mcna.2019.03.001.

29. Li R.X., Ma M., Xiao X.R., Xu Y., Chen X.Y., Li B. Perimenopausal Syndrome and Mood Disorders in Perimenopause: Prevalence, Severity, Relationships, and Risk Factors. Medicine (Baltimore). 2016;95(32):e4466. doi: 10.1097/MD.0000000000004466.

30. Yang D., Haines C.J., Pan P., Zhang Q., Sun Y., Hong S. et al. Menopausal Symptoms in Mid-Life Women in Southern China. Climacteric. 2008;11(4):329–336. doi: 10.1080/13697130802239075.

31. Wang H.L., Booth-LaForce C., Tang S.M., Wu W.R., Chen C.H. Depressive Symptoms in Taiwanese Women during the Peri- and Post-Menopause Years: Associations with Demographic, Health, and Psychosocial Characteristics. Maturitas. 2013;75(4):355–360. doi: 10.1016/j.maturitas.2013.04.021.

32. Unsal A., Tozun M., Ayranci U. Prevalence of Depression among Postmenopausal Women and Related Characteristics. Climacteric. 2011;14(2):244–251. doi: 10.3109/13697137.2010.510912.

33. Freeman E.W., Sammel M.D., Lin H. Temporal Associations of Hot Flashes and Depression in the Transition to Menopause. Menopause. 2009;16(4):728–734. doi: 10.1097/gme.0b013e3181967e16.

34. Bromberger J.T., Kravitz H.M., Chang Y.F., Cyranowski J.M., Brown C., Matthews K.A. Major Depression during and after the Menopausal Transition: Study of Women’s Health Across the Nation (SWAN). Psychol Med. 2011;41(9):1879–1888. doi: 10.1017/S003329171100016X.

35. Pizova N.V., Pizov A.V. Panic and Depressive Disorders in Clinical Practice. Poliklinika = Polyclinic. 2020;(6):16–19. (In Russ.) Available at: http://www.poliklin.ru/imagearticle/20206/16-19.pdf.

36. Bromberger J.T., Matthews K.A., Schott L.L., Brockwell S., Avis N.E., Kravitz H.M. et al. Depressive Symptoms during the Menopausal Transition: the Study of Women’s Health Across the Nation (SWAN). J Affect Disord. 2007;103(1–3):267–272. doi: 10.1016/j.jad.2007.01.034.

37. Freeman E.W., Sammel M.D., Lin H., Nelson D.B. Associations of Hormones and Menopausal Status with Depressed Mood in Women with No History of Depression. Arch Gen Psychiatry. 2006;63(4):375–382. doi: 10.1001/archpsyc.63.4.375.

38. Schmidt P.J., Haq N., Rubinow D.R. A Longitudinal Evaluation of the Relationship between Reproductive Status and Mood in Perimenopausal Women. Am J Psychiatry. 2004;161(12):2238–2244. doi: 10.1176/appi.ajp.161.12.2238.

39. Soares C.N. Mood Disorders in Midlife Women: Understanding the Critical Window and Its Clinical Implications. Menopause. 2014;21(2):198–206. doi: 10.1097/GME.0000000000000193.

40. Worsley R., Bell R., Kulkarni J., Davis S.R. The Association between Vasomotor Symptoms and Depression during Perimenopause: A Systematic Review. Maturitas. 2014;77(2):111–117. doi: 10.1016/j.maturitas.2013.11.007.

41. Natari R.B., Clavarino A.M., McGuire T.M., Dingle K.D., Hollingworth S.A. The Bidirectional Relationship between Vasomotor Symptoms and Depression across the Menopausal Transition: A Systematic Review of Longitudinal Studies. Menopause. 2018;25(1):109–120. doi: 10.1097/GME.0000000000000949.

42. De Kruif M., Spijker A.T., Molendijk M.L. Depression during the Perimenopause: A Meta-Analysis. J Affect Disord. 2016;206:174–180. doi: 10.1016/j.jad.2016.07.040.

43. Reed S.D., Ludman E.J., Newton K.M., Grothaus L.C., LaCroix A.Z., Nekhlyudov L. et al. Depressive Symptoms and Menopausal Burden in the Midlife. Maturitas. 2009;62(3):306–310. doi: 10.1016/j.maturitas.2009.01.002.

44. Vivian-Taylor J., Hickey M. Menopause and Depression: Is There a Link? Maturitas. 2014;79(2):142–146. doi: 10.1016/j.maturitas.2014.05.014.

45. Santoro N., Epperson C.N., Mathews S.B. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015;44(3):497–515. doi: 10.1016/j.ecl.2015.05.001.

46. Darwish M., Atlantis E., Mohamed-Taysir T. Psychological Outcomes after Hysterectomy for Benign Conditions: A Systematic Review and MetaAnalysis. Eur J Obstet Gynecol Reprod Biol. 2014;174:5–19. doi: 10.1016/j.ejogrb.2013.12.017.

47. Gibson C.J., Joffe H., Bromberger J.T., Thurston R.C., Lewis T.T., Khalil N., Matthews KA. Mood Symptoms after Natural Menopause and Hysterectomy with and without Bilateral Oophorectomy among Women in Midlife. Obstet Gynecol. 2012;119(5):935–941. doi: 10.1097/AOG.0b013e31824f9c14.

48. Rocca W.A., Grossardt B.R., Geda Y.E., Gostout B.S., Bower J.H., Maraganore D.M. et al. Long-Term Risk of Depressive and Anxiety Symptoms after Early Bilateral Oophorectomy. Menopause. 2018;25(11):1275–1285. doi: 10.1097/GME.0000000000001229.

49. Chou P.H., Lin C.H., Cheng C., Chang C.L., Tsai C.J., Tsai C.P. et al. Risk of Depressive Disorders in Women Undergoing Hysterectomy: A Population-Based Follow-Up Study. J Psychiatr Res. 2015;68:186–191. doi: 10.1016/j.jpsychires.2015.06.017.

50. Wilson L., Pandeya N., Byles J., Mishra G. Hysterectomy and Incidence of Depressive Symptoms in Midlife Women: the Australian Longitudinal Study on Women’s Health. Epidemiol Psychiatr Sci. 2018;27(4):381–392. doi: 10.1017/S2045796016001220.

51. Mulhall S., Andel R., Anstey K.J. Variation in Symptoms of Depression and Anxiety in Midlife Women by Menopausal Status. Maturitas. 2018;108: 7–12. doi: 10.1016/j.maturitas.2017.11.005.

52. Terauchi M., Hiramitsu S., Akiyoshi M., Owa Y., Kato K., Obayashi S. et al. Associations among Depression, Anxiety and Somatic Symptoms in Periand Postmenopausal Women. J Obstet Gynaecol Res. 2013;39(5): 1007–1013. doi: 10.1111/j.1447-0756.2012.02064.x.

53. Vorobieva O.V., Rusaya V.V. Anxiety Disorders in Neurological Practice. Lechaschiу Vrach. 2017;(5):12. (In Russ.) Available at: https://www.lvrach.ru/2017/05/15436718.

54. Whiteley J., DiBonaventura M.d., Wagner J.S., Alvir J., Shah S. The Impact of Menopausal Symptoms on Quality of Life, Productivity, and Economic Outcomes. J Womens Health (Larchmt). 2013;22(11):983–990. doi: 10.1089/jwh.2012.3719.

55. Uguz F., Sahingoz M., Gezginc K., Ayhan M.G. Quality of Life in Postmenopausal Women: the Impact of Depressive and Anxiety Disorders. Int J Psychiatry Med. 2011;41(3):281–292. doi: 10.2190/PM.41.3.g.

56. Sowislo J.F., Orth U. Does Low Self-Esteem Predict Depression and Anxiety? A Meta-Analysis of Longitudinal Studies. Psychol Bull. 2013;139(1):213–240. doi: 10.1037/a0028931.

57. Woods N.F., Mitchell E.S., Adams C. Memory Functioning among Midlife Women: Observations from the Seattle Midlife Women’s Health Study. Menopause. 2000;7(4):257–265. Available at: https://journals.lww.com/menopausejournal/Abstract/2000/07040/Memory_Functioning_Among_Midlife_Women_.8.aspx.

58. Greendale G.A., Huang M.H., Wight R.G., Seeman T., Luetters C., Avis N.E. et al. Effects of the Menopause Transition and Hormone Use on Cognitive Performance in Midlife Women. Neurology. 2009;72(21):1850–1857. doi: 10.1212/WNL.0b013e3181a71193.

59. Zhang L., Ruan X., Cui Y., Gu M., Mueck A.O. Menopausal Symptoms and Associated Social and Environmental Factors in Midlife Chinese Women. Clin Interv Aging. 2020;15:2195–2208. doi: 10.2147/CIA.S278976.

60. Akhapkin R.V., Bukreeva N.D., Vazagaeva T.I., Kostyukova E.G., Mazo G.Eh., Mosolov S.N. Depressive episode, recurrent depressive disorder (adults): clinical guidelines. Moscow; 2016. (In Russ.) Available at: https://medi.ru/klinicheskierekomendatsii/depressivnyj-epizod-rekurrentnoe-depressivnoe-rasstrojstvovzroslye_13916/

61. Bandelow B., Lichte T., Rudolf S., Wiltink J., Beutel M.E. The Diagnosis of and Treatment Recommendations for Anxiety Disorders. Dtsch Arztebl Int. 2014;111(27–28):473–480. doi: 10.3238/arztebl.2014.0473.

62. Zweifel J.E., O’Brien W.H. A Meta-Analysis of the Effect of hormone Replacement Therapy upon Depressed Mood. Psychoneuroendocrinology. 1997;22(3):189–212. doi: 10.1016/s0306-4530(96)00034-0.

63. Ghazanfarpour M., Kaviani M., Abdolahian S., Bonakchi H., Najmabadi Khadijeh M., Naghavi M., Khadivzadeh T. The Relationship between Women’s Attitude towards Menopause and Menopausal Symptoms among Postmenopausal Women. Gynecol Endocrinol. 2015;31(11):860–865. doi: 10.3109/09513590.2015.1056138.

64. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321–333. doi: 10.1001/jama.288.3.321.

65. Bond A., Lader M. A Comparison of the Psychotropic Profiles of Tofisopam and Diazepam. Eur J Clin Pharmacol. 1982;22(2):137–142. doi: 10.1007/BF00542458.

66. Bernard P., Dufresne-Favetta C., Favetta P., Do Q.T., Himbert F., Zubrzycki S. et al. Application of Drug Repositioning Strategy to TOFISOPAM. Curr Med Chem. 2008;15(30):3196–3203. doi: 10.2174/092986708786848488.

67. Petócz L. Pharmacologic Effects of Tofizopam (Grandaxin). Acta Pharm Hung. 1993;63(2):79–82. Available at: https://pubmed.ncbi.nlm.nih.gov/8100112/.

68. Srivastava S., Bhatia M.S., Gupta K., Rajdev K. Current Update on Evidence Based Literature of Tofisopam. Delhi Psychiatry J. 2014;17(1):154–159. Available at: https://www.researchgate.net/profile/Kartikeya-Rajdev/publication/323746367_Current_Update_on_Evidence_Based_Literature_of_Tofisopam/links/5aa9a9b9aca272d39cd5df79/Current-Update-onEvidence-Based-Literature-of-Tofisopam.pdf.

69. Pellow S., File S.E. Is Tofisopam an Atypical Anxiolytic? Neurosci Biobehav Rev. 1986;10(2):221–227. doi: 10.1016/0149-7634(86)90026-6.

70. Szegó J., Somogyi M., Papp E. Excerpts from the Clinical-Pharmacologic and Clinical Studies of Grandaxin. Acta Pharm Hung. 1993;63(2):91–98. Available at: https://pubmed.ncbi.nlm.nih.gov/8100114/.

71. Vakhrushev Ia.M., Belova E.V., Efremova LI. Use of Grandaxine in the Treatment of Patients with Erosive-Ulcerative Stomach and Gastroduodenal Lesions. Eksp Klin Gastroenterol. 2004;(4):21–24. Available at: https://pubmed.ncbi.nlm.nih.gov/15568662/.

72. Plotnikova E.Iu., Beloborodova E.I. Use of Grandaxin in Hypermotor Dysfunction of the Biliary Ducts in Young People. Eksp Klin Gastroenterol. 2005;(6):65–70, 113–114. Available at: https://pubmed.ncbi.nlm.nih.gov/17378391/.

73. Leventer S.M., Raudibaugh K., Frissora C.L., Kassem N., Keogh J.C., Phillips J., Mangel A.W. Clinical Trial: Dextofisopam in the Treatment of Patients with Diarrhoea-Predominant or Alternating Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2008;27(2):197–206. doi: 10.1111/j.1365-2036.2007.03566.x.

74. Manabe N., Rao A.S., Wong B.S., Camilleri M. Emerging Pharmacologic Therapies for Irritable Bowel Syndrome. Curr Gastroenterol Rep. 2010;12(5):408–416. doi: 10.1007/s11894-010-0124-1.

75. Klebovich I., Abermann M. Pharmacokinetics and Metabolism of Tofizopam (Grandaxin). Acta Pharm Hung. 1993;63(2):83–90. Available at: https://pubmed.ncbi.nlm.nih.gov/8100113/.

76. Markin S.P., Markina V.A., Artemov A.N., Chuprina S.E., Natarova E.B., Esin A.A. The Use of the Tranquilizer Grandaxin in the Treatment of Psychovegetative Syndrome. Prikladnye informatsionnye aspekty meditsiny = Applied Information Aspects of Medicine. 2008;11(1):84–86. (In Russ.) Available at: https://new.vestnik-surgery.com/index.php/2070-9277/article/download/5319/5317.

77. Evtushenko I.D., Zinkevich Ya.S., Kutsenko I.G., Belokrylova M. F. Efficiency of Using Grandaxin in Patients with Neuropsychic form of Premenstrual Syndrome. Problemy reproduktsii = Reproduction Problems. 2004;10(6):76–81. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=29934747.

78. Solovieva A.D., Buyachinskaya A.I. Grandaxin in the Treatment of Premenstrual Syndrome. Lecheniye nervnykh bolezney = Treatment of Nervous Diseases. 2001;3(5–2):29–31. (In Russ.) Available at: https://medi.ru/info/1664/.

79. Sokolova Т.М., Yagovkina N.V. Correction of the Vegetative, Psychological and Emotional Symptoms of Climacteric Synrome. Problemy reproduktsii = Reproduction Problems. 2014;(6):92–94. (In Russ.) doi: 10.17116/repro201420692-94.

80. Gribacheva I.A., Zhukova N.G. Vegeto-Correcting and Anxiolytic Action of Tofisopam in the Premenopausal Period. Vrach = The Doctor. 2010;(5):52–57. (In Russ.) Available at: https://medi.ru/info/2089/.

81. Pasechnikov V.D., Glukhova T.V., Umanskaya I.Yu., Septa I.G. Correction of Psychosomatic Disorders in the Complex Therapy of Arterial Hypertension in Women in the Perimenopausal Period. Yuzhno-Rossiyskiy meditsinskiy zhurnal = South-Russian Medical Journal. 2002;(3):26–32. (In Russ.) Available at: https://medi.ru/info/4435/.

82. Dobrokhotova Y.E., Saprykina L.V. Tofisopam: Prospects for Non-Hormonal Therapy of Neuro-Vegetative and Psycho-Emotional Disorders Associated with Menopausal Syndrome. Meditsinskiy sovet = Medical Council. 2017;(2):88–91. (In Russ.) doi: 10.21518/2079-701X-2017-2-88-91.

83. Freeman E.W., Guthrie K.A., Caan B., Sternfeld B., Cohen L.S., Joffe H. et al. Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial. JAMA. 2011;305(3):267–274. doi: 10.1001/jama.2010.2016.

84. Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A. et al. Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes. J Clin Oncol. 2002;20(6):1578–1583. doi: 10.1200/JCO.2002.20.6.1578.

85. Joffe H., Guthrie K.A., LaCroix A.Z., Reed S.D., Ensrud K.E., Manson J.E. et al. Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2014 Jul;174(7):1058–1066. doi: 10.1001/jamainternmed.2014.1891.

86. Guthrie K.A., LaCroix A.Z., Ensrud K.E., Joffe H., Newton K.M., Reed S.D. et al. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstet Gynecol. 2015;126(2):413– 422. doi: 10.1097/AOG.0000000000000927.

87. Orleans R.J., Li L., Kim M.J., Guo J., Sobhan M., Soule L., Joffe H.V. FDA Approval of Paroxetine for Menopausal Hot Flushes. N Engl J Med. 2014;370(19):1777–1779. doi: 10.1056/NEJMp1402080.

88. Pinkerton J.V., Kagan R., Portman D., Sathyanarayana R., Sweeney M. Phase 3 Randomized Controlled Study of Gastroretentive Gabapentin for the Treatment of Moderate-to-Severe Hot Flashes in Menopause. Menopause. 2014;21(6):567–573. doi: 10.1097/GME.0b013e3182a7c073.

89. Hayes L.P., Carroll D.G., Kelley K.W. Use of Gabapentin for the Management of Natural or Surgical Menopausal Hot Flashes. Ann Pharmacother. 2011;45(3):388–394. doi: 10.1345/aph.1P366.

90. Lavigne J.E., Heckler C., Mathews J.L., Palesh O., Kirshner J.J., Lord R. et al. A Randomized, Controlled, Double-Blinded Clinical Trial of Gabapentin 300 versus 900 mg versus Placebo for Anxiety Symptoms in Breast Cancer Survivors. Breast Cancer Res Treat. 2012;136(2):479–486. doi: 10.1007/s10549-012-2251-x.

91. Smits J.A., Berry A.C., Tart C.D., Powers M.B. The Efficacy of CognitiveBehavioral Interventions for Reducing Anxiety Sensitivity: A Meta-Analytic Review. Behav Res Ther. 2008;46(9):1047–1054. doi: 10.1016/j.brat.2008.06.010.

92. Herring M.P., Lindheimer J.B., O’Connor P.J. The Effects of Exercise Training on Anxiety. Am J Lifestyle Med. 2013;8(6):388–403. doi: 10.1177/1559827613508542.

93. Smits J.A., Berry A.C., Rosenfield D., Powers M.B., Behar E., Otto M.W. Reducing Anxiety Sensitivity with Exercise. Depress Anxiety. 2008;25(8): 689–699. doi: 10.1002/da.20411.